Login to Your Account



Cytogen Selling PSMA Joint Venture Share To Progenics

By Karen Pihl-Carey


Tuesday, April 25, 2006
Seven years after forming a joint venture for cancer immunotherapies based on prostate specific membrane antigen, Cytogen Corp. agreed to sell its 50 percent ownership to partner Progenics Pharmaceuticals Inc. in a deal potentially worth more than $65 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription